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Beckwith–Wiedemann syndrome (BWS) is a multisystem 
human genomic imprinting disorder with variable clinical 
expression and complex molecular aetiology1. BWS is an 
overgrowth syndrome, with patients often presenting with 
macroglossia, abdominal wall defects, hemihy perplasia 
(lateralized overgrowth), enlarged abdominal organs 
and an increased risk of embryonal tumours during early 
childhood. BWS is caused mainly by genetic or epigenetic 
defects within the chromosome 11p15.5 region2. This 
region contains imprinted genes, such as CDKN1C and 
IGF2, which are strong regulators of fetal growth. Although 
BWS might present prenatally or in adult life, it is most 
commonly diagnosed in the neonatal period or in early 
childhood, with an estimated prevalence of 1 affected child 
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Abstract | Beckwith–Wiedemann syndrome (BWS), a human genomic imprinting disorder, is 
characterized by phenotypic variability that might include overgrowth, macroglossia, abdominal 
wall defects, neonatal hypoglycaemia, lateralized overgrowth and predisposition to embryonal 
tumours. Delineation of the molecular defects within the imprinted 11p15.5 region can predict 
familial recurrence risks and the risk (and type) of embryonal tumour. Despite recent advances in 
knowledge, there is marked heterogeneity in clinical diagnostic criteria and care. As detailed  
in this Consensus Statement, an international consensus group agreed upon 72 recommendations 
for the clinical and molecular diagnosis and management of BWS, including comprehensive 
protocols for the molecular investigation, care and treatment of patients from the prenatal period 
to adulthood. The consensus recommendations apply to patients with Beckwith–Wiedemann 
spectrum (BWSp), covering classical BWS without a molecular diagnosis and BWS-related 
phenotypes with an 11p15.5 molecular anomaly. Although the consensus group recommends a 
tumour surveillance programme targeted by molecular subgroups, surveillance might differ 
according to the local health-care system (for example, in the United States), and the results of 
targeted and universal surveillance should be evaluated prospectively. International collaboration, 
including a prospective audit of the results of implementing these consensus recommendations, is 
required to expand the evidence base for the design of optimum care pathways.
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per 10,340 live births3. Since the first descriptions half a 
century ago, a PubMed search (conducted on 15 November 
2016) for “Beckwith Wiedemann”, “Wiedemann Beckwith” 
or “EMG syndrome” yielded >1,500 BWS-related articles. 
However, clinical practice varies regarding the diagnosis 
and care of individuals with BWS.
To address these issues, the European Cooperation 
in Science and Technology (COST)-funded European 
Network for Congenital Imprinting Disorders initiated 
a BWS consensus programme that involved an exten-
sive literature review, preparation and critical appraisal 
of draft documents and a final face-to-face consensus 
meeting involving invited experts and patient group rep-
resentatives. This effort produced a series of consensus 
recommendations for the diagnosis and care of individu-
als with the newly defined Beckwith–Wiedemann spec-
trum (BWSp), which are presented in this Consensus 
Statement.
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Methods
A PubMed search using the keywords “Beckwith 
Wiedemann”, “Wiedemann Beckwith” or “EMG syn-
drome” yielded articles of interest that were selected on the 
basis of the abstracts, with particular consideration given 
to the number of patients included and the description 
of the molecular mechanisms. Only articles mentioning 
the molecular mechanisms were retained. Articles were 
then reviewed by at least two experts and sorted into three 
groups: clinical diagnosis (group 1); molecular diagnosis 
(group 2); and clinical management (group 3).
The international BWS consensus group comprised 
41 participants from 36 institutions across 11 countries, 
predominantly based in Europe, including clinicians, 
clinical and research scientists and patient group rep-
resentatives with expertise in different aspects of BWS 
(clinical and molecular geneticists, paediatric endo-
crinologists, oncologists, orthopaedists, oro-facial sur-
geons and nephrologists). A modified Delphi consensus 
process was adopted4. Discussions occurred via confer-
ence calls, email communications and file exchanges. 
Two face-to-face meetings were held: a preliminary 
meeting of 11 participants (including one patient group 
representative) in February 2016 to identify the key 
issues to be addressed by the consensus group and a ple-
nary 3-day meeting involving 35 participants (including 
2 patient group representatives) in March 2017. During 
this plenary meeting, experts participated in one of the 
three subgroups (clinical, molecular or management) on 
the basis of their field of expertise, discussed the draft 
consensus documents and formulated and voted on 
the consensus recommendations (BOX 1). This Consensus 
Statement summarizes the outcome of these discussions 
and is divided into three subject areas: clinical aspects; 
molecular aspects; and care and management.
Clinical aspects of BWS
Since the seminal descriptions by Beckwith5 and 
Wiedemann6 in the 1960s, there have been many 
attempts to define BWS by use of various clinical crite-
ria that have been reported with different prevalences 
in cohorts of BWS (Supplementary information S1 
(table)); however, no agreed clinical definition of BWS 
has emerged. Since the findings in the 1990s of molec-
ular abnormalities of chromosome 11p15.5 in BWS7–9, 
it has been recognized that these genetic and epigenetic 
changes are frequently mosaic and lead to a range of clin-
ical phenotypes. These include ‘classical BWS’ (OMIM 
#130650), which is characterized by macroglossia, ante-
rior abdominal wall defects and prenatal and postnatal 
overgrowth, among other symptoms (Supplementary 
information S1 (table)), and some cases of isolated lat-
eralized overgrowth (previously called ‘isolated hemi-
hypertrophy’ or ‘isolated hemihyperplasia’; OMIM 
#235000)10 in addition to patients with a chromosome 
11p15.5 molecular anomaly who do not fit into these 
first two groups, a condition termed ‘atypical BWS’ by 
this consensus group. Given the overlapping pheno-
types and common molecular mechanisms between 
these groups, the consensus group decided that these 
phenotype and/or genotype combinations could be best 
classified as parts of the BWSp (TABLE 1, R1)and that the 
recommendations of this consensus should be applied 
to individuals with BWSp (FIG. 1; TABLE 1).
Clinical features of BWSp
BWS has classically been characterized by macroglossia, 
macrosomia, abdominal wall defects and an increased 
risk of embryonal tumours11–17. There is growing recog-
nition that not all patients with BWS display all of these 
phenotypic features and that patients have remained 
undiagnosed because they did not present with one of 
these features, such as macrosomia, which was initially 
considered as a cardinal feature but is present in only one-
half of the patients with an 11p15.5 molecular defect18,19. 
The clinical features outlined as part of the consensus 
BWSp scoring system include features that, when present, 
are more likely to lead to a positive diagnosis (termed 
‘cardinal features’), including macroglossia, exompha-
los, lateralized overgrowth, multifocal Wilms tumour 
or nephroblastomatosis, hyperinsulinism and specific 
pathology findings (such as adrenal cytomegaly or pla-
cental mesenchymal dysplasia) (BOX 2). Macrosomia has 
been defined according to different criteria in different 
clinical cohorts11–13,15–17, making it challenging to assess 
the role it has as a cardinal feature. Lateralized over-
growth is the novel term for hemihypertrophy (or hemi-
hyperplasia), which is defined as asymmetric overgrowth 
of part of the body10. Embryonal tumours such as Wilms 
tumours and hepatoblastoma can occur outside of the 
diagnostic scope of BWSp; however, multifocal Wilms 
tumours are more likely to occur in BWSp. As a cardinal 
feature, hyperinsulinism is defined as prolonged hypo-
glycaemia in the context of elevated insulin levels that 
last >1 week and/or require escalated treatment20, while 
transient hypoglycaemia resolves without the need for 
further intervention. Although pathology findings can-
not always be evaluated (especially when BWSp is not 
suspected prenatally or at birth and when placental sam-
ples are not collected), the diagnosis of BWSp should 
be considered in cases of adrenal cortex cytomegaly, 
placental mesenchymal dysplasia and pancreatic adeno-
matosis5. Additionally, if samples are available (especially 
from the placenta after birth) and the diagnosis is being 
considered, pathological investigation can be beneficial 
in making the clinical diagnosis.
Box 1 | Details of the consensus voting process
For voting on individual recommendations, participants (n = 33) selected from the 
following options (patient group representatives did not vote):
• A. Evidence or general agreement allow full agreement with the recommendation
• B. Evidence or general agreement are in favour of the recommendation
• C. Evidence or general agreement are weak for the recommendation
• D. There is not enough evidence or general agreement to agree with the 
recommendation
Depending on the proportion of votes received, the strength of the recommendation was 
recorded as follows:
• +, 26–49% of the votes
• ++, 50–69% of the votes
• +++, ≥70% of the votes
C O N S E N S U S  S TAT E M E N T
NATURE REVIEWS | ENDOCRINOLOGY  VOLUME 14 | APRIL 2018 | 231
©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
Features characterized as ‘suggestive features’ are 
likely to occur independently in the general paediatric 
population and are therefore given less weight in the 
consensus BWSp scoring system outlined in the next 
section. Suggestive features include a birthweight greater 
>2 standard deviation scores (SDS), facial naevus flam-
meus, polyhydramnios or placentomegaly, ear creases 
or pits, transient hypoglycaemia, embryonal tumours, 
nephromegaly or hepatomegaly and umbilical hernias 
or diastasis recti.
Consensus scoring system and definition
The many previously proposed systems to define BWS 
have suggested various combinations of clinical features 
(with macroglossia, exomphalos and/or (asymmetric) 
overgrowth as major features)11–13,18,21,22 with the aim of 
optimizing the likelihood of a classical and molecularly 
confirmed diagnosis. Frequently cited and recent pheno-
type articles from the past 25 years were reviewed for the 
prevalence of individual clinical features (Supplementary 
information S1 (table)), which were then classified as 
cardinal or suggestive features (BOX 2). As several of these 
articles referenced the same patient cohorts12–16,18,21–26, data 
were analysed from the nine articles describing apparently 
distinct cohorts11,12,14,15,18,21,23,25,26. The goal of this BWSp 
scoring system (TABLE 1; BOX 2) was to recognize that BWS 
falls into a clinical spectrum and that some features that 
have long been considered to be classical parts of the syn-
drome are not present in every patient, and therefore, the 
diagnosis should not be dismissed owing to the absence 
of such features. Additionally, this Consensus Statement 
sought to include elements that could be pathognomonic 
for BWS. In addition to informing the presence of a diag-
nosis of classical BWS, the consensus group also deter-
mined that the same system could be used to provide 
guidance regarding when to pursue genetic testing. We 
compared this new scoring system with previously pub-
lished systems (Supplementary information S2 (figure)) 
while keeping in mind that previous systems focused on 
the diagnosis of classical BWS and molecularly confirmed 
BWS and not the diagnosis of the BWSp.
Cardinal features are considered key to the clinical 
diagnosis, whereas suggestive features add to the like-
lihood of a clinical diagnosis and the indications for 
molecular testing but are less specific (BOX 2). Cardinal 
and suggestive feature designations were analysed in the 
BWSp cohort reported by Ibrahim et al.11 and were shown 
to be largely superior to previous diagnostic systems 
(Supplementary information S2 (figure)). Limitations of 
the study were that transient hypoglycaemia versus pro-
longed hyperinsulinism were not typically distinguished 
in the prior cohorts, so this feature could therefore not 
be assessed, and that macrosomia was variably defined 
in previous cohorts11–14,17,18,21,22.
Table 1 | Consensus recommendations of the clinical working group
R Recommendation Strength of 
recommendation
BWSp scoring system and clinical indications for molecular testing for BWS
1 BWSp is usually caused by dysregulation of the chromosome 11p15 imprinted region and involves overgrowth in multiple 
tissues, often in a mosaic state. BWSp encompasses a range of phenotypes, and children might present with one or more 
features (summarized in BOX 2). Classical BWS and lateralized overgrowth (‘hemihypertrophy and/or hemihyperplasia’) 
are considered subsets of the BWSp (FIG. 1). A third subset is defined as patients with an 11p15 anomaly who do not fit into 
these first two groups
A+++
2 There have been many proposed systems to define classical BWS, which have suggested combinations of macroglossia, 
omphalocele/exomphalos and/or (asymmetric) overgrowth. Although often associated, increased height and/or weight 
(macrosomia) are no longer considered a cardinal feature of BWS. For simplicity and consistency, we have developed 
consensus criteria (TABLE 2): a score of ≥4 must be reached for a diagnosis of classical BWS. Children who meet these 
criteria would be considered to have BWSp, even if an 11p15 anomaly is not identified
A+++
3 BWSp lateralized overgrowth is defined as a marked increase in the length and/or girth of most or all of one side of the 
body compared with its contralateral side in addition to an 11p15 abnormality. A child with an 11p15 anomaly who does 
not meet the criteria for classical BWS or BWSp lateralized overgrowth is still considered to be part of the BWSp. There are 
currently insufficient data to determine the management guidelines for patients with lateralized overgrowth without an 
identified 11p15 anomaly in tested samples; this group falls outside the scope of this consensus
A+++
4 We recommend molecular testing in anyone suspected of being in the BWSp (lateralized overgrowth, classical BWS or 
features in TABLE 2). For simplicity, we recommend molecular testing for any patient with ≥2 points. In cases where isolated 
omphalocele and/or exomphalos is present, testing can be considered at the discretion of the physician. Testing is also 
recommended with a family history of a parent with heritable pathogenic 11p15 anomaly, which places the child at a 50% 
risk of being affected. First tier testing is blood lymphocyte DNA
A+++
5 Hypoglycaemia is defined as plasma glucose levels <50 mg/dl for the first 6 hours of life and <60 mg/dl thereafter. 
Hyperinsulinism is defined as a glucose infusion rate of ≥8 mg/kg/min, a detectable level of insulin and/or C‑peptide and 
undetectable levels of ketones and free fatty acids. Transient hypoglycaemia as a suggestive feature is defined by the above 
criteria lasting <1 week. Hyperinsulinism as a cardinal feature is defined by these criteria lasting >1 week and/or requiring 
escalated treatment
A++
BWS and ART
6 There is an established association between ART and BWS. The absolute risk of BWS in an individual conceived by ART is 
estimated to be very low (no more than 1 in 1,000). Additional research is required to further characterize this association 
and the relationship between subfertility, hormonal stimulation, embryo manipulation and imprinting defects
A+++
ART, assisted reproduction technology; BWS, Beckwith–Wiedemann syndrome; BWSp, Beckwith–Wiedemann spectrum.
C O N S E N S U S  S TAT E M E N T
232 | APRIL 2018 | VOLUME 14 www.nature.com/nrendo
©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
Cardinal features include macroglossia, exomphalos, 
lateralized overgrowth, multifocal Wilms tumour, pro-
longed hyperinsulinism and distinct pathologic findings 
that are unique to BWS. The major differences between 
the consensus and previous scoring systems are the clas-
sification of macrosomia and hyperinsulinism. Although 
it is often associated with BWSp, macrosomia (defined 
as height and/or weight >2 SDS) is no longer considered 
a cardinal feature, as it is variably defined in previous 
cohorts and it might be present in only approximately one-
half of patients with BWS16,26. Hyperinsulinism (defined 
in TABLE 1, R5) without another identifiable molecular 
cause can be the initial presenting feature of BWSp27,28. 
Hyperinsulinism is classified as a cardinal feature when 
lasting >1 week and requiring escalated treatment and as 
a suggestive feature when lasting <1 week.
For simplicity and consistency, we have developed 
consensus criteria by use of cardinal and suggestive fea-
tures (TABLE 1, R2). For a clinical diagnosis of classical 
BWS, a patient requires a score of ≥4 based on cardinal 
and suggestive features; this clinical diagnosis does not 
require the molecular confirmation of an 11p15.5 anom-
aly. Patients with a score of ≥2 (including those with 
classical BWS with a score of ≥4) merit genetic testing 
according to our algorithm for investigation and diagno-
sis of BWS (FIG. 2). Patients with a score of <2 do not meet 
the criteria for genetic testing. Patients with a score of ≥2 
with negative genetic testing should be considered for an 
alternative diagnosis and/or referral to a BWS expert for 
further evaluation.
Clinical diagnosis within the BWSp beyond the clear 
diagnosis of classical BWS or a clear molecular diagnosis 
is challenging and requires a combination of molecular 
testing and physician opinion. There is currently not 
enough published data to provide clear clinical recom-
mendations for patients with a score of <4 who have no 
molecular abnormality. Nonetheless, patients with a 
cardinal feature of BWS (such as macroglossia, hyper-
insulinism, a multifocal Wilms tumour or a pathological 
finding) should be referred to a specialist with expertise 
in BWS for further evaluation. Patients with isolated 
exomphalos are more common and are less likely to have 
an 11p15.5 defect compared with patients with other iso-
lated symptoms, and should therefore not be included in 
the BWSp. Lateralized overgrowth can occur both as a 
symptom of BWSp and independent of BWSp10. When 
lateralized overgrowth occurs with an 11p15 abnormal-
ity, it is considered part of BWSp. As there are multiple 
molecular causes of lateralized overgrowth aside from 
11p anomalies (for example, PIK3CA and AKT1 muta-
tions), lateralized overgrowth without an 11p15 anomaly 
in a child who does not meet the criteria for classical 
BWS was considered to be outside the BWSp and the 
scope of this Consensus Statement; thus, recommenda-
tions for further investigation and clinical management 
were not made (TABLE 1, R3).
Indications for molecular testing
The consensus group recommended that molecular 
testing is indicated in patients with a score of ≥2 (BOX 2) 
unless there is an alternative explanation (for example, 
gestational diabetes mellitus for macrosomia) (TABLE 1, 
R4). For isolated exomphalos, molecular testing is dis-
cretionary. Testing is recommended in patients with a 
family history and a known heritable pathogenic 11p15 
anomaly (a positive family history might occur in 
10–15% of patients2,29). Some features included in some 
previous diagnostic criteria (for example, cleft palate, 
advanced bone age, polydactyly and supernumerary 
nipples) are suggestive of an alternative diagnosis such 
as Simpson–Golabi–Behmel syndrome30 and are there-
fore not included in the consensus scoring system. 
Although renal abnormalities are common in patients 
with BWSp, they are usually present with other features 
and not as an isolated feature. When molecular testing is 
negative, other relevant disorders should be considered 
in the differential diagnosis (FIG. 2; see Supplementary 
information S3 (table)).
Assisted reproduction technology
Assisted reproductive technologies (ARTs) are defined as 
treatments handling male and female gametes outside of 
the body and include procedures such as in vitro fertiliza-
tion (IVF) and intracytoplasmic sperm injection (ICSI)31. 
ARTs account for 1–3% of all births in industrialized coun-
tries31. Although these techniques are regarded as safe, it 
has been suggested that the establishment and/or main-
tenance of DNA methylation at imprinted loci might be 
disturbed by ART31–36. Following reports of children with 
a rare molecular subtype of Angelman syndrome who 
were conceived by ICSI32,33 and an increased frequency 
(~4–6-fold) of ART births in children with BWS34–36, a 
population-based study estimated the risk of BWS in 
IVF-conceived children to be approximately 1 in 4,000, 
substantially greater than that in the general population31. 
A study from 2017 reported a tenfold increased risk of 
BWS with ART but an absolute risk of approximately 
1 in 1,000 (REF. 37). Although some epidemiological stud-
ies have not detected an increased relative risk of BWS in 
children born after ART38,39, molecular studies support an 
association, as >90% of children with BWS conceived by 
Figure 1 | The Beckwith–Wiedemann spectrum. The consensus group introduced the 
concept of the Beckwith–Wiedemann spectrum (BWSp), which includes patients with a 
clinical diagnosis of Beckwith–Wiedemann syndrome (BWS) with or without an (epi)
genetic change at the BWS locus on chromosome 11p15, patients with ‘atypical BWS’ 
(defined as fewer cardinal and suggestive features than those needed for a clinical 
diagnosis of BWS) and an (epi)genetic change at the BWS locus, and patients with 
‘isolated lateralized overgrowth’ and an (epi)genetic change at the BWS locus. The 
dotted arrow indicates that some patients with apparent isolated lateralized overgrowth 
and no 11p15 abnormality might subsequently be found to have an 11p15 abnormality 
on testing of additional tissues or with a more sensitive assay. Patients with clinical BWS 
and no detectable 11p15 abnormality might be further investigated with additional 
clinical evaluation and consideration of other syndromes, which may have features 
overlapping with BWSp, and appropriate testing for those syndromes may be warranted.
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ARTs have an epimutation at the centromeric imprint-
ing centre KCNQ1OT1:transcriptional start site (TSS) 
differentially methylated region (DMR) (also known as 
IC2), compared with ~50% of children with BWS who 
were not conceived by ART40. Various factors might con-
tribute to an association between ARTs and Angelman 
syndrome or BWS, including infertility per se (that is, 
independently to ART techniques)41,42, superovulation or 
in vitro embryo culture43–45. The link between ART and 
epigenetic defects has also been suggested by the large 
offspring syndrome (an ART-associated phenomenon 
in sheep and cows that has some phenotypic similar-
ity to BWS), which has been reported to be associated 
with epigenetic alterations similar to those observed in 
BWS46. However, although there is clear evidence link-
ing ARTs and BWS, additional research is required to 
further elucidate the relationships between subfertil-
ity, hormonal stimulation, embryo manipulation and 
imprinting defects (TABLE 1, R6).
Molecular aspects of BWSp
BWSp is associated with molecular abnormalities affect-
ing a cluster of imprinted genes located within the chro-
mosome region 11p15.5–11p15.4, which is divided into 
two functionally independent domains: the centromeric 
and telomeric domains2 (FIG. 3). Each domain harbours 
its own imprinting control region, marked by a DMR. 
The insulin-like growth factor 2 (IGF2)-encoding gene 
(IGF2) and the gene encoding the non-translated long 
non-coding RNA (lncRNA) H19 are located in the tel-
omeric domain and are controlled by the H19/IGF2: 
intergenic (IG) DMR (also known as imprinting control 
region 1 (ICR1), H19-DMR or Imprinting Centre 1 
(IC1); OMIM *616186). The cell cycle inhibitor gene 
CDKN1C and the gene encoding the regulatory lncRNA 
KCNQ1OT1 are located in the centromeric domain 
and are controlled by the KCNQ1OT1:TSS DMR (also 
known as KvDMR, LIT1‑DMR, imprinting control 
region 2 (ICR2) or Imprinting Centre 2 (IC2); OMIM 
*604115). The Human Genome Variation Society 
(HGVS)-recommended nomenclature, H19/IGF2:IG 
DMR and KCNQ1OT1:TSS DMR, should be adopted in 
publications and test reporting47 (TABLE 2, R7); however, 
for brevity, IC1 and IC2 are used hereafter.
A molecular defect affecting imprinted genes in chro-
mosome region 11p15 can be demonstrated in ~80% of 
patients with BWSp2. DNA methylation abnormalities 
are the most frequent defects; loss of methylation (LOM) 
at the maternal IC2 allele is found in ~50% of patients and 
gain of methylation (GOM) at the maternal IC1 allele in 
5–10% of patients48. Mosaic, segmental paternal unipa-
rental isodisomy (UPD) of 11p15.5 (commonly referred 
to as segmental upd(11)pat) can be detected in 20% of 
patients, intragenic CDKN1C mutations can be detected 
in 5% of sporadic and 40% of familial cases, and chromo-
somal abnormalities in 11p15 can be detected in <5% of 
patients; a molecular diagnosis is not reached in up to 20% 
of patients2. The frequency of twinning is markedly higher 
in patients with BWS than the general population; in the 
majority of cases, twins are female, monozygous and dis-
cordant (that is, one twin is affected and one is unaffected 
by BWSp)49. Owing to the sharing of circulation during 
development, DNA from blood cells or saliva might show 
aberrant DNA methylation (usually IC2 LOM) in both 
affected and unaffected discordant twins, whereas methyl-
ation is concordant with phenotype in non-blood-derived 
samples such as buccal swab50. Thus, buccal swab is the 
preferred source of DNA for unambiguous diagnosis in 
cases of discordant monozygotic twins.
Molecular genetic testing for BWSp
A flowchart summarizing the molecular diagnostic path-
way for investigation of suspected BWSp is presented in 
FIGURE 2 (TABLE 2, R8).
First-line molecular testing procedures should assay 
IC1 and IC2 methylation (TABLE 2, R9). Methylation is 
abnormal in cases of IC2 LOM, IC1 GOM, copy number 
variations (CNVs) and segmental upd(11)pat (both IC2 
LOM and IC1 GOM)51. Abnormal methylation status 
confirms a diagnosis of BWSp, but its underlying mech-
anism must be established to define management, genetic 
counselling and recurrence risks48,51. Thus, if methylation 
is assayed using a technique that does not estimate DMR 
copy number, this should then be determined in all 
patients with IC1 and/or IC2 methylation abnormalities 
(FIG. 2). Currently, methylation-specific (MS) multiplex 
ligation-dependent probe amplification (MS-MLPA) is 
the most common diagnostic test, as it simultaneously 
detects DMR methylation status and copy number; how-
ever, other techniques (such as MS-PCR and MS quanti-
tative PCR) are more sensitive in patients with low-level 
mosaicism (for a detailed list, see REFS 51–54 and the 
references within).
Box 2 |  Clinical features of Beckwith–Wiedemann spectrum
Cardinal features (2 points per feature)
• Macroglossia
• Exomphalos
• Lateralized overgrowth
• Multifocal and/or bilateral Wilms tumour or nephroblastomatosis
• Hyperinsulinism (lasting >1 week and requiring escalated treatment)
• Pathology findings: adrenal cortex cytomegaly, placental mesenchymal dysplasia or 
pancreatic adenomatosis
Suggestive features (1 point per feature)
• Birthweight >2 SDS above the mean
• Facial naevus simplex
• Polyhydramnios and/or placentomegaly
• Ear creases and/or pits
• Transient hypoglycaemia (lasting <1 week)
• Typical BWSp tumours (neuroblastoma, rhabdomyosarcoma, unilateral Wilms tumour, 
hepatoblastoma, adrenocortical carcinoma or phaeochromocytoma)
• Nephromegaly and/or hepatomegaly
• Umbilical hernia and/or diastasis recti
For a clinical diagnosis of classical Beckwith–Wiedemann syndrome (BWS), a patient requires  
a score of ≥4 (this clinical diagnosis does not require the molecular confirmation of an 11p15 
anomaly). Patients with a score of ≥2 (including those with classical BWS with a score of ≥4) merit 
genetic testing for investigation and diagnosis of BWS. Patients with a score of <2 do not meet 
the criteria for genetic testing. Patients with a score of ≥2 with negative genetic testing should be 
considered for an alternative diagnosis and/or referral to a BWS expert for further evaluation. 
BWSp, Beckwith–Wiedemann spectrum; SDS, standard deviation scores.
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Recommended investigations if testing for methyl-
ation abnormalities is positive. If a DMR CNV is 
implied using a PCR-based methodology (such as 
MS-MLPA), chromosome microarray analysis (such 
as oligo nucleotide polymorphism-based or single 
nucleotide polymorphism (SNP)-based arrays) should 
be considered to determine the nature and extent of the 
deletion or duplication, and karyotyping, fluorescence 
in situ hybridization or subtelomeric MLPA should be 
considered to identify possible chromosomal transloca-
tions54–57. Testing can then be extended to other family 
members as appropriate. A SNP-based array will also 
allow detection of uniparental disomy (and indeed 
mosaicism) if a CNV is not detected.
If IC1 GOM and IC2 LOM are detected without evi-
dence of CNV, mosaic segmental upd(11)pat is probable 
and can, if necessary, be confirmed using microsatellite 
analysis or SNP-based chromosome microarray analy-
sis58–61. SNP-based chromosome microarray is considered 
to be the most sensitive method to investigate low-level 
mosaic (for example, 1–5%) segmental upd(11)pat59. 
Mosaic paternal unidiploidy (that is, genome-wide pater-
nal UPD) affects up to 10% of patients with uniparental 
disomy and, as mosaic paternal unidiploidy is associated 
with additional clinical features and an increased risk 
of tumour development, further investigations (SNP 
array or microsatellite analysis) to detect this molecular 
abnormality should be considered62–67 (TABLE 2, R10).
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Does the patient meet 
clinical criteria for testing?
DNA methylation testing 
for H19/IGF2:IG DMR and
KCNQ1OT1:TSS DMR
CNV testing at 11p15.5*
Clinical criteria for molecular 
testing not met
Does the patient have clinical 
features of diﬀerential 
diagnosis?
Score <2
Score <4
Score 
≥4
Score ≥2
Mosaicism 
(other tissues)‡
Further tests for 
rare chromosomal 
abnormalities‡
CDKN1C analysis‡
Yes No
dup(11)(p15.5)pat§ upd(11)pat H19/IGF2:
IG DMR GOM
KCNQ1OT1:
TSS DMR LOM
CDKN1C LOF 
variant
Cascade testing for 
CDKN1C variant in 
the family
Negative
Negative
Negative
Negative
Positive
Positive
Positive
Molecular testing for
alternative diagnosis
What is the BWS 
clinical score?
• CMA to determine 
   nature and extent 
   of CNV
• Karyotype, FISH 
   and/or subtelomeric 
   MLPA analyses to 
   identify translocation
SNP-based CMA 
and/or microsatellite 
analysis to identify
paternal unidiploidy
Detailed analysis of
H19/IGF2:IG DMR
to identify pathogenic
SNV and/or small CNV
Clinical questions Recommended molecular testing Molecular testing to be consideredMolecular diagnosis
Alternative 
molecular 
diagnosis
Molecular
diagnosis not 
conﬁrmed
Classical BWS 
without molecular 
conﬁrmation
Figure 2 | Flowchart for investigation and diagnosis of Beckwith–
Wiedemann syndrome. The figure summarizes the molecular diagnostic 
pathway for investigation of suspected Beckwith–Wiedemann spectrum 
(BWSp). Patients with clinical features reaching a score of ≥2 should be 
genetically tested. It is recommended that first-line testing should assay the 
methylation status of H19/IGF2:intergenic (IG) differentially methylated 
region (DMR) (also known as IC1) and KCNQ1OT1:transcriptional start site 
(TSS) DMR (also known as IC2). If not estimated simultaneously with DNA 
methylation, DMR copy number should then be determined in all patients 
with IC1 and/or IC2 methylation abnormalities. These assays can yield 
positive molecular diagnosis of BWSp with IC2 loss of methylation (LOM), 
IC1 gain of methylation (GOM), segmental paternal uniparental isodisomy 
(UPD) of 11p15.5 (upd(11)pat) or copy number variation (CNV; most 
commonly duplication of paternal 11p15.5 (dup(11)(p15.5)pat)). Further 
molecular tests can be considered to determine underlying mechanism of 
methylation abnormality, UPD or CNV. If DNA methylation testing is 
negative, further molecular tests can be considered to identify mosaic 
methylation abnormalities, pathogenic CDKN1C variants or rare balanced 
chromosomal rearrangements. If all molecular tests are negative, 
differential diagnosis should be considered. However, a diagnosis of classical 
Beckwith–Wiedemann syndrome (BWS) is made in the presence of a clinical 
score of ≥4 even in the absence of the molecular confirmation of an 11p15 
anomaly. CMA, chromosome microarray analysis (can be oligonucleo-
tide-based and/or single-nucleotide-polymorphism-based platforms); FISH, 
fluorescence in situ hybridization; LOF, loss of function; MLPA, multiplex 
ligation-dependent probe amplification; SNP, single nucleotide 
polymorphism; SNV, single nucleotide variation. *CNV status may be 
determined simultaneously with methylation testing. ‡See main text for 
indications for testing. §Deletion of maternal 11p15.5 (del(11)(p15.5)mat) 
may be detected with lower frequency.
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Up to 20% of patients with IC1 GOM might carry 
small CNVs in the DMR, which cannot be detected 
using chromosome microarray analysis, or single nucle-
otide variations (SNVs) in octamer-binding protein 4 
(OCT4; also known as POU domain, class 5, transcrip-
tion factor 1) or transcription factor SOX binding sites; 
these CNVs and SNVs are associated with a high risk 
of recurrence68–74. Although some small CNVs can be 
detected using MS-MLPA, detection of SNVs would 
require additional investigations that are unavailable in 
most diagnostic laboratories (TABLE 2, R11). However, 
targeted IC1 sequencing can be considered in a special-
ized laboratory if MS-MLPA shows IC1 GOM and no 
CNV, especially if there is a family history of BWSp.
IC2 LOM is the most common epigenetic finding in 
BWSp, but IC2 DMR deletions are rare55, and at present, 
there is no indication for analysing patients with BWSp 
and IC2 LOM for SNVs. Approximately one-third of 
patients with IC2 LOM have multilocus imprinting 
disturbance (MLID)75–78. In most patients, the clinical 
importance of MLID is uncertain, and therefore, routine 
testing for MLID is not usually indicated; however, in 
patients with IC2 LOM and a family history of BWSp 
and no IC2 DMR CNV, MLID testing might help to 
determine if further testing for trans‑acting mutations 
should be considered79,80.
Recommended investigations if first-line molecular test-
ing is negative. A negative result for first-line molecular 
testing for IC1 and IC2 methylation does not exclude 
BWSp for a variety of reasons, including the possibility 
of low-level mosaicism that is below the limit of detec-
tion of methylation testing, a CDKN1C mutation, a rare 
balanced chromosomal rearrangement (for example, 
inversion and/or translocation), an unrecognized or 
undetected cause of BWSp (~20% of patients with a 
characteristic BWS phenotype remain without a molecu-
lar diagnosis2) or an incorrect clinical diagnosis (TABLE 2, 
R12–15). Further molecular testing should be prioritized 
according to the most probable cause; for example, a less 
severe phenotype with lateralized overgrowth would 
suggest mosaicism, whereas a classical BWS phenotype 
with an abdominal wall defect and a positive family 
history would indicate a potential CDKN1C mutation.
Mosaicism for the molecular defect occurs in most 
sporadic cases of BWSp, and different tissues might have 
different proportions of affected cells81. First-line diag-
nostic testing is usually performed using blood-leukocyte 
DNA, and IC1 or IC2 methylation level might be equiv-
ocal or within the normal range. Analysis of DNA from 
buccal swabs, cultures of fibroblasts or cells of mesenchy-
mal origin (for example, obtained from surgical resec-
tion and/or excision of hyperplastic tissues) improve the 
detection rate for all mosaic defects51,54,81 (TABLE 2, R13).
CDKN1C mutations account for ~5% of sporadic 
cases of BWS and for 40% of familial cases (in the case of 
maternal inheritance)48,82. Detection of a candidate path-
ogenic CDKN1C variant enables appropriate cascade 
testing to clarify familial recurrence risks82,83. Rare cases 
of apparently de novo CDKN1C mutations can arise in 
siblings, presumably resulting from maternal germline 
mosaicism83.
Rare maternally inherited balanced translocations or 
inversions involving chromosome region 11p15 might 
or might not be associated with IC2 methylation anom-
alies and should be considered if first-line testing is neg-
ative84–87 (TABLE 2, R14). Finally, when molecular testing 
is negative, other relevant disorders should be consid-
ered as differential diagnoses (FIG. 2; TABLE 2, R15; see 
Supplementary information S3 (table)).
Multilocus imprinting disturbance
MLIDs are those with altered DNA methylation in addi-
tion to the lesion responsible for the primary clinical pres-
entation88. MLID has a higher prevalence in BWSp than 
in other imprinting disorders, and genome-wide analyses 
have revealed MLID in approximately one-third of patients 
with BWSp who have IC2 LOM but not in patients with 
segmental upd(11)pat or IC1 GOM48,75–78,81,88–91. In BWSp, 
MLID almost exclusively involves loci methylated in the 
maternal, and not the paternal, germ line, although rare 
cases show LOM at both IC2 and IC1 (the latter finding is 
a feature of the growth restriction disorder Silver–Russell 
syndrome (SRS))76,92.
Rare cases of BWSp-MLID have been associated with 
biallelic maternal-effect genetic mutations in NLRP2 
(REF. 79) and NLRP5 (REF. 80) (which encode NACHT, 
LRR and PYD domains-containing protein 2 (NLRP2) 
and NLRP5), and therefore, the possibility of an under-
lying trans‑acting genetic mutation in these genes may 
warrant consideration in genetic counselling.
Perhaps owing to the various methylation alterations 
and frequent mosaicism seen in MLID, its effect on the 
BWS clinical phenotype remains unclear75,76,78,89,92,93, 
and therefore, routine clinical diagnostic testing is not a 
recommendation of this consensus.
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Figure 3 | The Beckwith–Wiedemann syndrome locus at chromosome 11p15.5.  
The figure depicts the chromosome 11p15.5–11p15.4 region with the imprinted genes 
and control regions that are implicated in the pathophysiology of Beckwith–Wiedemann 
spectrum (BWSp). The BWSp locus can be divided into two functionally independent 
domains, the telomeric and centromeric domains. Each domain harbours its own 
imprinting control region that is differentially methylated on the maternal and paternal 
chromosomes. The insulin-like growth factor 2 (IGF2)-encoding gene (IGF2) and the gene 
encoding the non-translated long non-coding RNA H19 are located in the telomeric 
domain and are controlled by the H19/IGF2:intergenic (IG) differentially methylated 
region (DMR) (also known as IC1), which is methylated on the paternal chromosome. The 
cell cycle inhibitor gene CDKN1C and the gene encoding the regulatory long 
non-coding RNA KCNQ1OT1 are located in the centromeric domain and are controlled 
by the KCNQ1OT1:transcriptional start site (TSS) DMR (also known as IC2),  
which is methylated on the maternal chromosome. Genes expressed from the  
maternal chromosome are depicted as red boxes, and genes expressed from the paternal 
chromosome are depicted as blue boxes. Grey boxes indicate non-expressed alleles. 
Filled lollipops indicate methylated imprinting centres (ICs), and open lollipops indicate 
unmethylated ICs. Bent arrows indicate the orientation of transcription.
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Recurrence risks in BWSp
The risk of recurrence for BWSp depends on the genetic 
aetiology and nature of any genetic or epigenetic defect 
identified as well as its parental origin. It is therefore rec-
ommended that family counselling should be performed 
by an individual experienced in the field of imprinting 
disorders and should take into account the precise nature 
of the anomaly detected (TABLE 2, R16,17).
It has been reported that up to 10–15% of cases of 
BWSp are familial and most commonly result from 
CDKN1C mutations, chromosome 11p15 abnormalities 
and genetic alterations within IC1 (REFS 2,29). In these 
cases, the mode of inheritance is autosomal dominant, 
but the recurrence risk is dependent on the sex of the par-
ent transmitting the affected allele (TABLE 2, R17; TABLE 3).
Pathogenic CDKN1C variations have a 50% recur-
rence risk with variable expressivity if the mutation is 
inherited from the mother82,83. In principle, all 11p15 
CNVs and balanced translocations have a 50% recur-
rence risk with phenotypes dependent on the paren-
tal origin54,84,86,87. In cases with paternal duplication of 
11p15 resulting from the unbalanced segregation of a 
translocation or an inversion, individuals carrying the 
balanced rearrangement have a normal phenotype94. In 
some pedigrees, either BWSp or SRS has been observed 
depending upon paternal or maternal transmission of 
the 11p15 duplication57,95,96. Paternal transmission of a 
duplicated telomeric domain and maternal transmission 
of a deleted centromeric domain also usually result in 
BWSp with a high recurrence risk52,95,97,98. Prediction of 
Table 2 | Consensus recommendations of the molecular working group
R Recommendation Strength of 
recommendation
Molecular genetic analysis
7 Molecular genetic testing should be performed by a health professional experienced in the field of imprinting disorders. 
Recommended nomenclature (for example, HGVS) should be adopted in publications and in test reporting
A+++
8 The flowchart outlined in FIG. 2 should be followed for molecular diagnosis of BWSp A+++
9 First-line molecular testing should include DNA methylation analysis of the H19/IGF2:IG DMR (IC1) and KCNQ1OT1:TSS 
DMR (IC2) regions. If a DNA methylation defect at either or both DMRs is found, further tests should be performed to 
identify possible underlying CNV or upd(11)pat (if it was not discriminated in initial diagnostic testing)
A+++
10 Given the different tumour spectrum associated with mosaic genome-wide paternal uniparental disomy, further testing 
should be considered to distinguish this condition from upd(11)pat
A+++
11 Detailed analysis of the H19/IGF2:IG DMR should be considered in individuals with GOM of this region, as SNVs and/or 
small CNVs can occur in these patients and confer high risk of recurrence (prioritized in the presence of a positive family 
history)
A+++
12 In patients with a negative methylation test result, second-line molecular testing should be considered and might include 
sequencing of the coding exons and the exon–intron boundaries of CDKN1C (prioritized in the presence of a positive 
family history, a cleft palate or an abdominal wall defect (umbilical hernia or exomphalos))
A+++
13 In patients with a negative methylation test result, second-line molecular testing should be considered and might include 
analysis of additional tissues to detect somatic mosaicism (prioritized in the presence of asymmetric overgrowth)
A+++
14 In patients with a negative methylation test result, second-line molecular testing should be considered and might include 
further tests for rare chromosomal rearrangements
A+++
15 In patients with a negative methylation test result, second-line molecular testing should be considered, and might include 
re-evaluation of the clinical diagnosis and reconsideration of differential diagnoses
A+++
16 Genetic counselling should be performed by a health professional experienced in the field of imprinting disorders A+++
17 As the recurrence risk associated with genetic defects (for example, CDKN1C loss of function variants, CNVs and DMR 
SNVs) is dependent on their size, location and parental origin, these factors should be taken into consideration during 
counselling for the family
A+++
Prenatal molecular genetic analysis
18 Prenatal molecular diagnostic investigations should be considered if prenatal ultrasonography reveals potential features 
of BWSp and should lead to a specific diagnosis (or exclude other potential conditions); they should also be considered if 
a positive family history with a known molecular defect is present, which would influence the management of the relevant 
pregnancy
A+++
19 The flowchart indicated for postnatal testing (FIG. 2) is not necessarily applicable to prenatal testing. Modification of this 
flowchart depends on the individual setting (for example, known molecular defects and specific clinical features)
A+++
20 Prior to offering prenatal diagnosis for BWSp, a detailed discussion of the technological limitations and ethical issues 
should be undertaken with the parents; in particular, they should be made aware that a normal result does not necessarily 
exclude the diagnosis
A+++
21 It is recommended that centres offering prenatal diagnosis prospectively collect information on the true/false positive/
negative diagnostic rates and that this information is contributed to multicentre audits to enable best practice guidelines 
to be further developed and refined
A+++
BWSp, Beckwith–Wiedemann spectrum; CNV, copy number variation; DMR, differentially methylated region; GOM, gain of methylation; HGVS, Human Genome 
Variation Society; SNV, single nucleotide variant; upd(11)pat, segmental paternal uniparental isodisomy of 11p15.5. 
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phenotypes and recurrence risks that are associated with 
smaller CNVs within either the telomeric or centromeric 
domain can be complex, as it depends on their size and 
the genes and regulatory elements involved55,99–104.
Internal IC1 CNVs and SNVs have recurrence risk 
as high as 50% when occurring on the maternal allele, 
although incomplete penetrance and possible anticipation 
have been observed in some cases73,105,106. Rare familial 
cases of BWSp-MLID might be caused by maternal- effect 
gene mutations (for example, NLRP2 or NLRP5 muta-
tions) and might be associated with a very high recur-
rence risk79,80. In the patients that harbour other molecular 
defects, the recurrence risk is generally low (TABLE 3).
Prenatal molecular diagnosis
Prenatal testing for BWSp poses particular challenges 
because, in addition to general aspects of molecular 
testing (such as the range of molecular disturbances, the 
challenge of mosaicism detection and the technical limi-
tations of testing), the reliability and informative value of 
prenatal test results and the ethical issues involved must 
be considered before sampling107.
The major indications for prenatal diagnosis of BWSp 
are familial cases with a known genetic alteration and a 
high recurrence risk and patients with no family history 
in which possible features of BWSp (usually exomphalos 
but also macrosomia, hemihypertrophy, organomegaly 
and polyhydramnios) have been detected using prena-
tal fetal ultrasonography (TABLE 2, R18). The diagnostic 
testing for prenatal samples does not therefore necessar-
ily follow the same flow as that for postnatal samples but 
reflects the individual situation (TABLE 2, R19).
Although chorionic villus (CVS) cells, amniotic fluid 
cells or fetal blood cells (native and cultured) might be 
used for molecular testing, it is possible that cell culture 
might influence the methylation patterns108. In CVS 
cells, the methylation pattern at 11p15.5 might be differ-
ent from that of embryonic tissues108, and/or CVS cells 
might not reflect the (epi)genetic constitution of the 
fetus, and therefore, false-positive results might occur107. 
False-negative prenatal test results might occur with all 
types of testing owing to mosaicism; therefore, a normal 
prenatal test result cannot absolutely exclude a diagno-
sis of BWSp (TABLE 2, R20). Because of the fairly recent 
adoption of prenatal testing and the challenges involved, 
it is recommended that multicentre audit of cases, meth-
ods and diagnostic rates be implemented prospectively, 
to enable ongoing refinement of best practice guidelines 
(TABLE 2, R21).
Care and management aspects of BWSp
In view of the complex multisystem manifestations of 
BWSp, the consensus group recognized the requirement 
for effective coordination of health care (TABLE 4, R22).
Table 3 | Summary of Beckwith–Wiedemann spectrum molecular defect categories and recurrence risk
Molecular 
defect
Frequency of 
molecular defect
Mosaicism 
observed
Risk of recurrence Characteristic clinical features (compared 
with other molecular subgroups)
IC1 GOM 5%48 Yes27,54,76,78,81 • If no genetic anomaly is present, <1%2
• If genetic anomaly (for example, 
pathogenic SNV of copy number 
variant in the DMR) is present, 50%; 
dependent on parental origin71,73,105,106
• Low frequency of exomphalos11,14,17
• High risk of Wilms tumour14,58,149
IC2 LOM 50%48 Yes27,54,76,78,81 • If no genetic anomaly is identified, <1%2
• If a cis-acting genetic anomaly is 
present, 50%; dependent on parental 
origin99–103
• High frequency of exomphalos11,14,17
• Low risk of Wilms tumour14,58,149
upd(11)pat 20%48 (see 
also paternal 
unidiploidy)
Yes27,54,61,76,78,81 <1%2 • High incidence of lateralized overgrowth11,14
• Low frequency of exomphalos11,14,17
• High risk of Wilms tumour and 
hepatoblastoma14,58,149
Loss-of-function 
CDKN1C 
variants
5% (40% in familial 
cases)48
Usually no 
but has been 
reported rarely83
50% on maternal transmission82,83 • High frequency of exomphalos11,14,17
• Low risk of Wilms tumour14,58,149
dup(11)(p15.5)
pat
~2–4%55 No55 • 50% on paternal transmission55,94
• Risk of SRS on maternal 
transmission57,95,96
–
Deletions 
involving 11p15
1-2%55,98 No55 Dependent on extent and position of 
CNV, and parent of origin55
–
Mosaic paternal 
unidiploidy 
(genome-wide 
paternal UPD)
Up to 10% of 
upd(11)pat62–67,184
Yes62–67,184 Low62–67,184 High frequency of neoplasia63,64,137,152
MLID 33% of IC2 LOM 
cases75–78,88
Yes78,88–91 Low unless an in trans genetic variant is 
identified79,80
Unclear75,76,78,89,92,93
DMR, differentially methylated region; dup(11)(p15.5)pat, duplication of paternal 11p15.5; GOM, gain of methylation; LOM, loss of methylation; MLID, multilocus 
imprinting disturbance; SNV, single nucleotide variation; UPD, uniparental isodisomy; upd(11)pat, paternal uniparental isodisomy of 11p15.5.
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Table 4 | Recommendations of the management working group
R Recommendation Strength of 
recommendation
22 It is recommended that each patient with BWSp should have an experienced lead health-care provider who will organize 
the referral to each specialist and will coordinate care for the patient
A+++
Prenatal management
23 If a diagnosis of BWSp is suspected or confirmed in the prenatal period, then potential BWSp-related fetal and maternal 
complications (for example, fetal congenital anomalies, shoulder dystocia from macrosomia, postnatal hypoglycaemia and 
maternal preeclampsia) should be anticipated and appropriate clinical care should be performed
A+++
24 If a diagnosis of BWSp is suspected or confirmed in the prenatal period, then delivery should take place in a clinical facility 
where neonatal intensive care can be provided
A+++
Growth and lateralized overgrowth
25 Growth charts from BWSp patients are needed A+++
26 Physicians should be aware of the rare possibility of final height >2 SDS above the mean. Postnatal growth and pubertal 
development should be monitored at least annually until the end of growth
A++
27 Appropriate interventions might be proposed in the case of possible tall stature with the same procedures as for other 
patients with tall stature
A++
28 Monitoring of leg length discrepancy should be based on clinical examination A++ (LO)
29 Patients with BWSp should be monitored for LLD at least annually during childhood and referred to a paediatric orthopaedic 
surgeon if LLD is present
A+++ (LO)
30 Shoe‑lifts might be indicated for LLD <2 cm. Epiphysiodesis is usually indicated for predicted LLD >2 cm. Reversible 
epiphysiodesis might be preferred
A++ (LO)
31 Lengthening of the shorter normal limb should be considered only for specific cases A+++ (LO)
32 Surgical correction of asymmetric overgrowth of the upper limbs is generally not indicated A+++ (LO)
Management of macroglossia
33 If substantial airway obstruction is suspected, a careful evaluation including sleep studies (polysomnography) and/or 
pulmonologist consultation and ear, nose and throat consultation should be performed
A+++
34 Tongue reduction surgery should be considered usually after the age of 1 year if there are macroglossia‑associated feeding 
problems, persistent drooling, speech difficulties, dental malocclusion and psychosocial problems caused by the altered 
appearance
A+++
35 Surgical intervention (adenoid tonsillectomy with or without tongue reduction surgery) should be considered earlier in cases 
of severe airway obstruction
A+++
36 In cases of feeding difficulties, support from feeding specialists and dietetics should be proposed A+++
37 Tongue reduction surgery should be performed by an experienced surgical team after detailed assessment by a 
multidisciplinary team (including paediatric anaesthesiologists, intensive care unit members, surgeons, speech therapists 
and orthodontists), preferably in a reference centre
A+++
38 The results of surgery should be carefully audited, and postoperative follow‑up should continue until age 16 years A+++
Management of exomphalos
39 Treatment of exomphalos in the context of BWSp should be in accordance with general recommendations for the treatment 
of exomphalos; however, in BWSp-associated cases, attention should be paid to the risk of hypoglycaemia and the 
anaesthetic risks associated with severe macroglossia
A+++
Management of hypoglycaemia
40 Capillary blood glucose should be monitored in neonates with a clinical suspicion or confirmed diagnosis of BWSp for the 
first 48 hours of life. Hypoglycaemia should be defined by two consecutive (30 min) glucose levels <50 mg/dl (<2.75 mmol/l) 
during the first 6 hours of life or <60 mg/dl (<3.5 mmol/l) later. In case of hypoglycaemia, the newborn baby should be 
transferred to a neonatal intensive care unit
A++
41 A diagnostic fasting test (including measurement of glucose, insulin and ketones after 6 hours of fasting for full‑term babies 
and after 4 hours for preterm babies) should be performed 48 hours after birth and before discharge from the nursery for 
neonates with a suspicion of BWSp
A++
42 No specific management of hyperinsulinism and/or hypoglycaemia has been proposed in the context of BWSp, and 
management of hyperinsulinism and/or hypoglycaemia should be performed according to general recommendations
A++
43 In case of severe persistent hyperinsulinism in a patient with BWSp, additional causes of hyperinsulinism should be 
investigated
A+++
Management of cardiac lesions
44 Physicians should be aware of the increased prevalence of cardiac anomalies in children with BWSp A++
45 A baseline, clinical cardiovascular examination should be performed at diagnosis in all children with clinical and/or 
molecular diagnosis of BWSp. Individuals with clinically detected or suspected cardiovascular abnormalities should be 
referred for specialist cardiac assessment and echocardiography
A+++
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Table 4 (cont.) | Recommendations of the management working group
R Recommendation Strength of 
recommendation
Management of cardiac lesions (cont.)
46 Annual evaluation and electrocardiogram are recommended in patients with genomic rearrangements involving the IC2 region B+
47 Management and follow-up of congenital cardiac lesions (for example, ventricular septal defect) should be as in the 
population without BWSp
A+++
Management of neurological features
48 Cognitive development should be monitored by the paediatrician. Particular attention should be paid to those with risk 
factors such as preterm birth and neonatal hypoglycaemia and to carriers of chromosome rearrangements or paternal 
genome-wide UPD
A+++
49 For patients with a clinical diagnosis of BWSp and a learning disability with no molecular or chromosomal anomaly, other 
potential diagnoses should be considered and excluded (Supplementary information S3 (table))
A+++
50 Neurological investigations, including MRI, might be indicated only in children with neurological symptoms A++
Management of renal complications
51 At diagnosis of BWSp, all patients should be screened for nephro-urological malformations by clinical evaluation and USS A+++
52 Physicians should be aware of the possibility of hypercalciuria, which can lead to nephrocalcinosis A++
53 Patients with USS-detected anomalies should be referred to a paediatric nephrologist and urologist for specific follow-up A+++
54 For patients undergoing abdominal surveillance for tumour screening, physicians and radiologists should pay attention to 
the possibility of nephrocalcinosis and/or stones
A+++
55 For patients with BWSp, at the time of adult transition, a nephro-urological evaluation (clinical examination, blood pressure 
and USS) should be performed
A++
BWSp and embryonal tumours
56 Screening should be stratified according to the genotype A+++
57 Abdominal USS for BWSp‑related tumours every 3 months until age 7 years is recommended for all patients with BWSp 
except patients with isolated IC2 LOM
A++
58 For patients with BWSp and upd(11)pat, abdominal USS for Wilms tumour and hepatoblastoma every 3 months until age 
7 years is recommended
A+++
59 For patients with BWSp and IC1 GOM, abdominal USS for Wilms tumour every 3 months until age 7 years is recommended A+++
60 For patients with BWSp and IC2 LOM, no tumour surveillance is recommended *A/B+
61 For patients with BWSp and a CDKN1C mutation, abdominal USS for neuroblastoma every 3 months until age 7 years is 
recommended
A+
62 For patients with BWSp and an 11p15 duplication, abdominal USS for Wilms tumour every 3 months until age 7 years is 
recommended
A+++
63 For patients with classical BWS without a molecular defect, abdominal USS every 3 months until age 7 years is 
recommended
A++
64 α-Fetoprotein (AFP) screening is not recommended for patients with BWSp A+
65 Catecholamine screening is not recommended for patients with BWSp A+++
66 There should be a lower threshold for investigation in cases of possible tumour-related symptoms or in response to parental 
concerns
A+++
67 Treatment of tumours in patients with BWSp might be different from treatment of patients with sporadic diseases and 
should be discussed with respective study groups unless specific BWSp recommendations are given in the relevant tumour 
treatment protocols
A+++
Late-onset complications
68 Individuals with BWSp should be reviewed at age 16–18 years to identify any complications that will require continued 
follow-up by adult health-care services
A+++
69 Young adults with BWSp should be alerted to the availability of genetic counselling so that they can seek advice prior to 
starting a family
A+++
70 Given the paucity of data on the long-term health effects of a diagnosis of BWSp, further research should be undertaken A+++
Psychological and counselling aspects
71 Health professionals caring for children and families with BWSp should take a holistic approach to care and be prepared 
to offer referral to specialist counselling and family support services as required. Especially, psychological evaluation and 
support should be offered to children and their families if required
A+++
72 When the clinical diagnosis is confirmed, parents should be offered the contact details of BWSp support groups A+++
BWSp, Beckwith–Wiedemann spectrum; GOM, gain of methylation; LLD, leg length discrepancy; LO, lateralized overgrowth; LOM, loss of methylation; SDS, 
standard deviation scores; UPD, uniparental isodisomy; upd(11)pat, paternal uniparental isodisomy of 11p15.5; USS, ultrasound scan. *Equal numbers of 
participants chose option A and option B.
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Prenatal management
In patients with BWSp for whom a risk of recurrence has 
been identified (TABLE 3), some parents might wish to con-
sider prenatal diagnosis. If a molecular diagnosis is not 
available or indicated, then ultrasonographic detection 
of an anterior abdominal wall defect or macroglossia or, 
less specifically, macrosomia, visceromegaly, polyhydram-
nios, placentomegaly or pancreatic overgrowth might indi-
cate a likely diagnosis of BWSp109. Rarer manifestations 
detectable by prenatal ultrasound scan (USS) include pla-
cental mesenchymal dysplasia, urinary tract abnormalities, 
cardiac defects, adrenal cysts and masses110,111. Abnormal 
prenatal biochemical screening results — for example, ele-
vated levels of free β-human chorionic gonadotropin in the 
first trimester109–111 and/or increased α-fetoprotein (AFP) 
levels in the second trimester (associated with exomph-
alos)112 — can be associated with BWSp in the fetus. In 
pregnancies known to be at increased risk of BWSp, the 
presence of a single anomaly (for example, exomphalos) 
might be sufficient to make a presumptive diagnosis.
In pregnancies without a previous history of BWSp, 
none of the prenatally detectable features of BWSp are, 
in isolation, pathognomonic. Approximately 10–20% of 
fetuses with a prenatally diagnosed isolated exompha-
los112,113 and ~20% of those with placental mesenchymal 
dysplasia114 will have BWSp. As cytogenetic and/or chro-
mosome microarray analysis are indicated for both these 
findings, molecular analysis for BWSp can also be per-
formed on the same sample, and confirmation or exclusion 
of BWSp might be helpful for the parents. For less-specific 
features (for example, urinary tract abnormalities and 
cardiac defects), testing for BWSp is likely to depend on 
whether there are multiple BWSp-related features present.
When a prenatal diagnosis of BWSp is suspected or 
confirmed, the management of individual congenital 
anomalies (for example, exomphalos or cardiac defect) 
generally follows standard protocols based on usual local 
practices. However, macrosomia might cause problems 
(for example, shoulder dystocia) at delivery, and there-
fore, growth should be carefully monitored in the latter 
stages of pregnancy and appropriate arrangements for 
delivery should be made (TABLE 4, R23,24). BWSp is also 
associated with polyhydramnios and premature birth. 
Potential post-delivery complications such as neonatal 
hypoglycaemia, respiratory obstruction from macro-
glossia, surgical repair of exomphalos and so on should 
be anticipated, and appropriate monitoring and facilities 
should be put in place.
Maternal complications associated with a diagnosis of 
fetal BWSp include gestational hypertension (~2.4-fold 
increased risk) and pre-eclampsia115,116. In addition, 
haemolysis, elevated liver enzymes and low platelets 
(HELLP) syndrome has been reported occasionally in 
BWSp116,117. Therefore, in cases of a suspicion of fetal 
BWS, such a condition should be looked for with a lower 
threshold than with normal pregnancies.
Growth and lateralized overgrowth
Although prenatal and postnatal overgrowth have been 
considered to be cardinal features in previous reports, over-
growth occurs in only 43–65% of patients118. Overgrowth 
at birth might be relatively more common in patients 
with IC1 GOM and segmental pat(11)upd than in other 
molecular subgroups14,17. Postnatal growth is generally 
in the upper part of the normal range but usually slows 
in late childhood, and differences in growth trajecto-
ries between children with BWSp and those without it 
should be considered when making predictions of adult 
height. However, growth trajectories have not been well 
reported in patients with BWSp, and specific growth 
charts are needed (TABLE 4, R25). Although few data 
on final adult height are available, one study reported 
that final adult height was higher than parental tar-
get height, with a mean distance to target height of 
1.7 ± 1.1 SDS and approximately one-half of the patients 
having height SDS >2 (REF. 15) (TABLE 4, R26). Advanced 
bone age is infrequent (~3%)119,120, and to date, there are 
no data regarding treatment of tall stature in cohorts of 
patients with BWSp (TABLE 4, R27).
Lateralized overgrowth might occur in all molec-
ular subtypes of BWSp, but it is rare in patients with a 
CDKN1C mutation and is the most frequent feature in 
patients with segmental upd(11)pat11,14. Molecular abnor-
malities in region 11p15 might be observed in patients 
with isolated lateralized overgrowth, which enables a 
diagnosis of BWSp in such cases119,121. Leg length dis-
crepancy (LLD) can be associated with substantial mor-
bidity and can negatively influence quality of life122. The 
management of LLD will depend on severity (TABLE 4, 
R28–31). Shoe-lifts might be indicated for LLD <2 cm. 
As in isolated (non-BWSp) LLD, epiphysiodesis might be 
considered for LLD discrepancy >2 cm (REF. 123) (TABLE 4, 
R30). Surgical correction of asymmetric overgrowth of 
the upper limbs is generally not indicated (TABLE 4, R32).
Management of macroglossia
Of children diagnosed with classical BWS, 90% have 
macroglossia, and BWSp is the most common cause 
of macroglossia in childhood124. Although macroglossia 
might appear to regress spontaneously in some children 
(from a combination of a decrease in growth velocity and 
an increase in growth of the mandible), ~40% of children 
with BWS undergo a surgical tongue reduction125. The 
most common indications for surgery are problems with 
feeding; persistent drooling; difficulties with articula-
tion; orthodontic problems, including prognathism and 
development of an anterior open-bite and incisor spac-
ing and/or flaring; and psychosocial difficulties resulting 
from abnormal cosmetic appearance and difficulties with 
speech, feeding and drooling126–128 (TABLE 4, R33–35).
The enlarged tongue is usually increased in size in all 
three dimensions, and the aim of surgery is to reduce the 
tongue bulk while preserving normal shape and improv-
ing function. The most common surgical approach is 
anterior wedge resection, but a variety of other tech-
niques have been described125,128,129. Surgical complica-
tions, although infrequent, can include postoperative 
oedema of the tongue and wound dehiscence.
In rare cases, respiratory problems might require sur-
gery to be performed in the neonatal period, and preoper-
ative tracheostomy might be required125. When obstructive 
sleep apnoea is suspected, an airway evaluation and 
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appropriate further investigation with polysomnogra-
phy can be used for objective assessment130,131 (TABLE 4, 
R33). In the absence of respiratory obstruction, surgery 
is generally delayed until at least age 12 months (when 
tongue size is more stable) (TABLE 4, R34). If the indi-
cation for surgery is unclear, the child’s progress should 
be monitored to determine whether indications arise 
in the future. Long-term follow-up studies generally 
show favourable results of surgery in most cases, with 
cosmetic improvement, reduced drooling, resolution of 
feeding difficulties, improved speech, adequate tongue 
mobility and, usually, no substantial effect on taste sen-
sation126–128. Surgery has been reported to provide good 
outcomes in children who are operated on at a wide 
variety of ages but mainly in those who are operated on 
before 2–3 years125,127.
To facilitate objective assessments and accrual of accu-
rate long-term prognostic data, surgery should, when-
ever possible, be restricted to a small number of units 
that can offer a multidisciplinary service (including an 
experienced surgical team) and long-term follow-up 
(TABLE 4, R35–38).
Management of exomphalos
Exomphalos is a cardinal feature of BWSp (BOX 2) and 
is preferentially associated with molecular defects 
occurring within the centromeric domain (IC2 LOM 
or CDKN1C mutations)11,14,17. To date, no specific rec-
ommendations have been given regarding the manage-
ment of exomphalos occurring in patients with BWSp 
compared with isolated exomphalos in accordance with 
usual local practices (TABLE 4, R39).
Molecular investigations of apparently isolated exom-
phalos in neonates rarely detect a molecular abnormality 
in the absence of additional BWSp features132.
Management of hypoglycaemia
Hypoglycaemia in BWSp is due to excess insulin and 
occurs in 30–60% of children with BWSp11,14,17. Although 
BWSp-related neonatal hypoglycaemia is often transient 
and resolves within a few days, in up to 20% of neonates, 
it can persist beyond the first week of life and require 
medical treatments or even pancreatectomy in the most 
severe cases20.
Congenital hyperinsulinism is a rare condition with a 
range of causes20,133. In a cohort of 501 patients with 
hyperinsulinism (excluding patients with focal hyper-
insulinism), ~6% had features of BWSp (most of whom 
had segmental upd(11)pat), and half of these patients 
underwent surgery owing to persistent hypoglycaemia 
after optimal medication27.
Although low plasma glucose concentrations are 
common during the first 24 hours of life in all neonates, 
by day 3, plasma glucose concentrations in neonates are 
similar to those of older children, with a normal range of 
3.5–5.5 mmol/l (60–100 mg/dl)134. A diagnosis of hyper-
insulinism is based on evidence of increased insulin 
secretion and/or actions at the time of hypo glycaemia, 
including a detectable insulin level, suppressed levels of 
plasma β-hydroxybutyrate (ketones), suppressed lev-
els of plasma free fatty acids and a glycaemic response 
to glucagon. Diagnosis should be made in consul-
tation with an endocrinologist who is familiar with 
hyperinsulinism.
Neonates with suspected BWSp should be screened 
for hypoglycaemia (TABLE 4, R40,41) before discharge 
from the nursery. Neonates with confirmed hypo-
glycaemia should be treated to maintain a plasma glucose 
concentration >3.9 mmol/l (>70 mg/dl)134. Management 
of hyperinsulinism includes medical therapies such as 
diazoxide and somatostatin analogues (such as octreotide 
and lanreotide). Surgery (pancreatectomy) might be indi-
cated if persistent hypoglycaemia occurs despite maximal 
medical therapies135. New therapies such as mechanistic 
target of rapamycin (mTOR) inhibitors (sirolimus) or 
glucagon-like peptide 1 receptor (GLP1R) antagonists 
have been used in the treatment of hyperinsulinism and 
very recently in BWSp136; however, to date, no specific 
management (medical or surgical) for hyperinsulinism 
has been evaluated in the context of BWSp (TABLE 4, R42).
Two genes that are implicated in congenital hyper-
insulinism, ABCC8 and KCNJ11, map to chromosome 
11p, and some patients with BWSp might carry a hetero-
zygous mutation in either gene27, although these are rare. 
If these genes are included in the isodisomy, then homo-
zygosity for the mutation in disomic cells produces severe 
hypoglycaemia27. In cases of hypoglycaemia with hyper-
insulinism and without other traits suggestive of BWSp, 
investigations for 11p15.5 methylation abnormalities might 
be considered.
Management of cardiac lesions
Congenital heart disease is more prevalent in BWS 
than in the general paediatric population, and cardiac 
defects occur in up to 13–20% of patients with BWS12,17,23 
(TABLE 4, R44). Minor anatomical defects (for example, 
cardiomegaly, patent ductus arteriosus or patent foramen 
ovale and interatrial or interventricular defects) require 
echocardiographic monitoring until usual spontaneous 
resolution occurs (TABLE 4, R45). More severe defects 
might require surgical correction, although the man-
agement will be similar to that in sporadic cases of heart 
disease (TABLE 4, R47).
Congenital long QT syndrome has been reported in 
two families with BWS harbouring an intragenic deletion 
and a translocation at IC2 leading to inactivation of the 
KCNQ1 gene, which, although very rare, is associated 
with a risk of sudden death85,102 (TABLE 4, R46).
Management of neurological features
Cognitive development is usually normal in patients with 
BWSp; however, developmental delay can be associated 
with prematurity, severe hypoglycaemia, unbalanced 
chromosome rearrangements or paternal genome-wide 
UPD137 (TABLE 4, R48). The differential diagnosis should 
be carefully considered in patients with presumptive BWS 
and learning disability and without an 11p15 anomaly, 
as some overgrowth disorders (for example, Sotos syn-
drome, Malan syndrome and Simpson–Golabi–Behmel 
syndrome) are more frequently associated with devel-
opmental delay30,138–144 (TABLE 4, R49; see Supplementary 
information S3 (table)).
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Malformations of the central nervous system (for 
example, abnormal posterior fossae (including Dandy–
Walker malformations) or abnormal corpus callosum or 
septum pellucidum) have been reported in rare patients 
with BWSp (chiefly with a defect involving IC2)83,145, and 
these features might need to be considered in children 
with neurological symptoms or signs (TABLE 4, R50).
Management of renal complications
The prevalence of nephro-urological anomalies in 
BWSp is 28–61%146. A variety of anomalies have been 
described; cortical and medullary cysts occur in ~10% 
of patients with BWSp and the prevalence of hypercalci-
uria and nephrolithiasis is increased compared with that 
in the general population147. Although not all nephro- 
urological anomalies detected by ultrasonography will be 
of clinical importance, a minority of anomalies might be 
severe (and usually detectable prenatally) and require 
medical or surgical management. Severe vesicoureteral 
reflux might cause kidney damage and recurrent urinary 
tract infections148. In addition, nephromegaly might be 
a marker of increased risk of Wilms tumour146.
Renal anomalies might occur in all molecular subtypes 
of BWSp, but only certain groups might be offered regu-
lar renal imaging for tumour surveillance. Management 
of the nephro-urological aspects of BWSp should be 
pragmatic and balance the benefits of presymptomatic 
diagnosis and treatment of critical obstructions and 
urinary tract infections for preserving renal function 
with the drawbacks of over-investigation for benign 
variants detected by surveillance. Thus, we recommend 
a nephro-urological evaluation at clinical diagnosis and 
at the time of adult transition for any patient with BWSp 
and screening for nephrocalcinosis and/or stones in 
only patients who undergo abdominal USS for tumour 
screening (TABLE 4, R51–55).
BWSp and embryonal tumours
Embryonal tumours occur in ~8% of children with 
BWSp149. The most common types of embryonal 
tumours are Wilms tumour (52% of all tumours), hepa-
toblastoma (14% of all tumours), neuroblastoma (10% 
of all tumours), rhabdomyosarcoma (5% of all tumours) 
and adrenal carcinoma (3% of all tumours)14. Although 
there are some differences in mean age at diagnosis 
between tumour types, the overall cancer risk is highest 
in the first 2 years of life, and clinical experience suggests 
that the cancer risk then declines progressively before 
puberty, approaching the cancer risk of the general pop-
ulation. Currently, there is no evidence of an increased 
risk of malignant tumours in adulthood (Supplementary 
information S4 (table)).
The tumour risk correlates with the BWSp molecu-
lar subgroup; patients with segmental upd(11)pat and 
IC1 GOM have a higher tumour risk than patients with 
CDKN1C mutations and IC2 LOM58. The four main 
molecular subgroups are characterized by a cancer risk 
gradient, with the highest risk in cases of IC1 GOM 
(28% risk), followed by segmental upd(11)pat (16% 
risk), CDKN1C mutation (6.9% risk) and IC2 LOM 
(2.6% risk)14. In addition, there are also differences in the 
tumour types observed between molecular subgroups. 
Patients with IC1 GOM are mostly predisposed to devel-
oping Wilms tumour (observed in 24% of patients and 
accounting for 95% of malignancies in this group)14,15,149. 
Conversely, patients with IC2 LOM and CDKN1C muta-
tions do not usually develop Wilms tumour but rather 
develop other tumours such as hepatoblastoma, rhab-
domyosarcoma and neuroblastoma. Thus, a study from 
2016 reported a prevalence of Wilms tumour of ~0.2% 
(2/995) in patients BWSp and IC2 LOM149; although 
a report from 2017 suggested that the risk of Wilms 
tumour in patients with IC2 LOM is underestimated, 
only a single patient with Wilms tumour and an IC2 epi-
mutation was observed150. Therefore, when put together 
with previous reports of Wilms tumour in large cohorts 
of patients with BWSp, the overall prevalence of Wilms 
tumour with IC2 LOM is probably well below 1%151. 
Patients with CDKN1C mutations are mostly predisposed 
to neuroblastoma14,15,149. Patients with segmental upd(11)
pat are predisposed to develop any of the tumour types 
seen in BWSp (TABLE 5). Individuals with genome-wide 
paternal UPD seem to have a high risk of developing 
tumour types similar to those with segmental upd(11)
pat but with an increased incidence of hepatic and/or 
adrenal tumours extending into adolescence and young 
adulthood63,64,137,152.
Specific studies investigating the tumour risk in 
patients with isolated lateralized overgrowth and clin-
ically diagnosed BWS with negative molecular testing 
are lacking. It seems plausible that the cancer risk in 
patients with isolated lateralized overgrowth who fall 
within the BWSp is linked to the type of 11p15.5 molec-
ular anomaly. Indeed, the tumour risk in patients with 
isolated lateralized overgrowth and segmental upd(11)
pat is estimated to be as high as 32–50%121,153.
Tumour surveillance strategies
Tumour screening in patients with inherited cancer 
predisposition syndromes aims to improve patient sur-
vival and reduce morbidity through earlier detection of 
tumours. However, no surveillance protocol can detect 
every tumour, and there are both benefits and drawbacks 
to screening — the latter include the financial costs, 
morbidity that can result from investigating asymp-
tomatic benign lesions detected on surveillance and 
psychosocial burden of repeated investigations for the 
patient and family. There is no generally accepted risk 
threshold for instigating tumour screening strategies, 
and it might vary according to regional medical and 
medicolegal practices and local health-care systems. 
Although screening is considered for a tumour risk 
>1% in the USA, a risk of 5% might be considered an 
appropriate threshold in Europe10,154. Various protocols 
have been suggested for tumour surveillance in BWSp, 
usually comprising abdominal USS with or without 
measurement of AFP levels at various ages and inter-
vals during infancy14,15,155. Traditionally, although most 
protocols have been applied to all cases of BWSp, the 
definition of specific epigenotype–tumour risk corre-
lations provides a basis for more targeted surveillance 
protocols.
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Screening for Wilms tumour. Abdominal USS is the 
preferred modality for Wilms tumour screening. The 
doubling time of Wilms tumour cells has been esti-
mated to be 11–13 days156, and USS is recommended 
every 3–4 months157,158. Given the high survival of indi-
viduals with Wilms tumour (90% overall survival at 
4 years), early detection of Wilms tumour by surveil-
lance is predicted to only marginally impact survival; 
however, diagnosis at an earlier stage might reduce the 
burden of treatment-related morbidity159–162.
If Wilms tumour screening is targeted by BWSp 
molecular subgroup, patients with IC1 GOM and seg-
mental upd(11)pat are at the highest risk, and several 
groups have suggested that patients with IC2 LOM 
should not be screened using USS in order to avoid 
excessive medicalization and possible false-positive 
results149,154.
Screening for hepatoblastoma. The risk of hepato-
blastoma in patients with BWS is >2,000-fold higher 
than in the general population, and hepatoblastoma 
is the second most common tumour type in BWS21. 
However, specific studies evaluating hepatoblastoma 
screening in BWSp are lacking. Abdominal USS is a 
first-line investigation in children with a suspected liver 
mass, although not all parts of the liver can be imaged 
easily and small tumours might be missed159. Concerns 
about the sensitivity of abdominal USS led to suggestions 
that it should be combined with measurements of serum 
levels of AFP, which is secreted by >95% of hepato-
blastomas163–165. Treatment and outcome of patients with 
hepatoblastoma are closely connected to tumour stage at 
diagnosis, and preliminary data suggested that patients 
with BWSp and hepatoblastoma who are screened 
for AFP have an earlier stage at diagnosis and a better 
Table 5 | Proposed tumour surveillance protocol for Beckwith–Wiedemann spectrum
Tumour risk (% of patients)* Tumour type for surveillance Surveillance procedures Timing
IC2 LOM
• Overall risk (2.6%)
• Hepatoblastoma (0.7%)
• Rhabdomyosarcoma (0.5%)
• Neuroblastoma (0.5%)
• Thyroid cancer (0.3%)
• Wilms tumour (0.2%)
• Melanoma (0.1%)
Tumour incidence lower than other 
molecular subgroups; extremely 
variable tumour spectrum; only half 
of tumours arise in the abdomen
• No routine USS surveillance
• Clinical assessment and USS 
in response to signs and/or 
symptoms or parental concerns
–
IC1 GOM
• Overall risk (28.1%)
• Wilms tumour (24%)
• Neuroblastoma (0.7%)
• Pancreatoblastoma (0.7%)
Wilms tumour Abdominal USS Every 3 months from 
diagnosis until age 7 years
upd(11)pat
• Overall risk (16%)
• Wilms tumour (7.9%)
• Hepatoblastoma (3.5%)
• Neuroblastoma (1.4%)
• Adrenocortical carcinoma (1.1%)
• Phaeochromocytoma (0.8%)
• Lymphoblastic leukaemia (0.5%)
• Pancreatoblastoma (0.3%)
• Hemangiotheloma (0.3%)
• Rhabdomyosarcoma (0.3%)
• Wilms tumour
• Hepatoblastoma
• Adrenal tumours
Abdominal USS Every 3 months from 
diagnosis until age 7 years
CDKN1C mutation
• Overall risk (6.9%)
• Wilms tumour (1.4%)
• Neuroblastoma (4.2%)
• Acute lymphoblastic leukaemia (1.4%)
Neuroblastoma Abdominal USS Every 3 months from 
diagnosis until age 7 years
Classical BWS with negative molecular tests
• Overall risk (6.2%)
• Wilms tumour (4.1%)
• Neuroblastoma (0.6%)
• Hepatoblastoma (0.3%)
• Rhabdomyosarcoma (0.3%)
• Adrenocortical carcinoma (0.3%)
Wilms tumour Abdominal USS Every 3 months from 
diagnosis until age 7 years
Proposed tumour surveillance protocols for patients with Beckwith–Wiedemann spectrum (BWSp) disorder (including those with isolated lateralized overgrowth 
who have 11p15 abnormalities) are shown and stratified according to molecular subtype. Although there are differences in tumour risks and prevalent tumour 
types between molecular subgroups when surveillance is recommended, a single surveillance programme is used to reduce confusion and enhance consistency. In 
specific health-care systems, practice might currently vary from this protocol (see the main text for details). BWS, Beckwith–Wiedemann syndrome; GOM, gain of 
methylation; LOM, loss of methylation; upd(11)pat, paternal uniparental isodisomy of 11p15.5; USS, ultrasound scan. *Tumour and histotype prevalence data from 
Maas et al.14 and Mussa et al.17; 7 years refers to the risk of Wilms tumour, as hepatoblastoma usually occurs before age 2 years. 
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prognosis than unscreened patients and that increased 
serum AFP levels might precede hepatoblastoma detec-
tion by USS166. However, this hypothesis is unproved, 
and further data are required. In the paediatric setting, 
interpreting serum AFP levels can be complex owing 
to the wide range and variable concentrations in early 
infancy167,168. Serum AFP levels might be higher in babies 
with BWSp and without hepatoblastoma than in age-
matched healthy controls169. In view of the burden of 
repeated venepuncture and the complexity of interpret-
ing elevated AFP levels, it has been debated whether the 
benefits of AFP screening in BWSp outweigh the draw-
backs170–173, and the consensus voted not to recommend 
AFP screening (TABLE 4, R64).
Screening for neuroblastoma. Although reported in all 
BWSp molecular subgroups, neuroblastomas are pref-
erentially associated with CDKN1C mutations, with 
a frequency of ~4%14 (TABLE 5). Detection of asympto-
matic neuroblastomas by determination of the urinary 
tumour markers vanillylmandelic acid and homo vanillic 
acid and/or the catecholamine to creatinine ratio com-
bined with three monthly USSs until age 2–3 years has 
been suggested149. However, previous neuroblastoma 
screening strategies using urinary markers in large-
scale paediatric settings had a very minor influence on 
the related morbidity and mortality174,175, and there is 
currently no evidence that neuroblastoma screening in 
BWSp improves treatment and survival (TABLE 4, R65).
Surveillance for other tumour types. Screening for 
adrenal carcinoma can be undertaken using clinical 
evaluation, adrenal USS and determination of serum 
dehydroepiandrosterone sulfate concentrations every 
4–6 months176. However, adrenal carcinoma is rare in 
BWS (even in patients with genome-wide paternal UPD, 
who are at the highest risk), and there is no data on the 
utility of such screening strategies in BWSp.
Consensus tumour surveillance protocol
The consensus group agreed that tumour surveil-
lance should be targeted to those molecular subgroups 
of BWSp that are at highest risk and that children 
with BWSp and IC2 LOM should not be offered rou-
tine USS (TABLE 4, R60) (although, there should be a low 
threshold for investigation in response to symptoms or 
parental concern). Other BWSp molecular subgroups 
and patients with classical BWS and no detectable 
molecular anomaly should be offered abdominal USS 
every 3 months until age 7 years (TABLE 4, R57–59,61–63; 
TABLE 5). It was agreed that AFP measurements should 
not be offered routinely because the incidence of hepato-
blastoma was judged too low to warrant specific screen-
ing, the influence of surveillance of patients and families 
is unclear, and the difficulties in interpretation might 
lead to false-positive results (TABLE 4, R64). Nevertheless, 
in specific health-care systems, clinicians might cur-
rently vary from the proposed protocol, especially when 
regional protocols are available, pending the outcome 
of the results of prospective studies of targeted and 
universal surveillance.
The consensus surveillance protocol enables 
~50% of children with BWSp at low tumour risk to 
be spared 3 monthly USSs, and although the risk of 
Wilms tumour, for example, is small in patients with 
a CDKN1C mutation, applying a common surveillance 
modality (abdominal USS rather than renal USS in 
some subgroups, liver USS in other subgroups and so 
on) in all the groups to be screened avoids the poten-
tial for confusion with more complicated regimens. 
It should be noted that the agreed protocol differs 
from that recommended recently by the American 
Association for Cancer Research (AACR) Childhood 
Cancer Predisposition Workshop, which adopted a 1% 
risk threshold for surveillance and therefore recom-
mended abdominal USS and AFP screening for all cases 
of BWSp155. Both the AACR group and this consensus 
group made these decisions on the basis of similar data 
for tumour risks in different molecular subgroups but 
came to differing conclusions with regard to adopting a 
targeted screening approach. It should be noted that the 
AACR group consisted predominantly of experts from 
North America, whereas the international BWS consen-
sus group was composed predominantly of experts from 
European centres, where targeted screening has already 
been adopted in some countries14,154. Thus, the difference 
in screening recommendations between the two groups 
reflects mainly the different medical and medicolegal 
cultures in North America and Europe. Although a uni-
versally agreed upon screening protocol would usually 
be preferable, taking into account the different conclu-
sions between the experts of both the AACR group and 
this consensus group, it is reasonable that at this time, 
screening protocols could be different between Europe 
and North America. Such diversity of practice can be 
helpful, as careful audit of the results of the two protocols 
can help further refine our recommendations at future 
international consensus meetings155.
Management of BWSp-related tumours
Children with BWSp and Wilms tumour, when com-
pared with non-syndromic children with Wilms tumour, 
present with less metastatic disease because of earlier 
stage disease, fewer anaplastic tumours and a higher inci-
dence of bilateral synchronous or metachronous recur-
rence161 (TABLE 4, R67). The latter seem to be connected 
to the presence of multifocal or diffuse nephrogenic 
rests in one or both kidneys (nephroblastomatosis)177, 
a feature that is not easily distinguishable from Wilms 
tumour on standard imaging160. Although patients with 
BWSp and Wilms tumour who are diagnosed using 
abdominal USS surveillance have a smaller tumour size 
than children with sporadic Wilms tumour157, overall 
survival values are similar (at least 90% at 4 years)161. 
Smaller Wilms tumours are more amenable to partial 
nephrectomy and nephron-sparing strategies (such as 
partial nephrectomy) are particularly preferred in patients 
with BWSp given the potential co-occurrence of progres-
sive non-malignant renal diseases and bilateral Wilms 
tumours158. Data from 2016 show comparable outcomes 
after nephron-sparing surgery and total nephrectomy in 
patients with BWSp and Wilms tumour160.
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Late-onset complications
Features of BWSp such as macroglossia and postnatal 
overgrowth tend to ameliorate with age, and therefore, 
BWSp is often likely overlooked in adults unless there 
is a prior diagnosis in childhood. There is a paucity 
of information on long-term outcomes and late- onset 
complications in adults with BWSp (TABLE 4, R70). 
Concerns about potential adult-onset complications 
that are not directly related to childhood features of 
BWSp fall into four areas.
Neoplasia. Despite the link with embryonal neoplasia, 
there is no apparent association between BWSp and 
predisposition to common adult-onset carcinomas. 
Although rare endocrine tumours have been reported 
in adults with BWSp62,152,178–180 (Supplementary infor-
mation S4 (table)), there is no evidence of a specific 
tumour risk that might justify surveillance. However, 
follow-up of large series of adults with BWS has not 
been performed. Children with BWSp who are treated 
for embryonal tumours might develop late-onset com-
plications from surgery, radiotherapy or chemotherapy, 
similar to children with sporadic tumours.
Cardiovascular defects. Patients with congenital heart 
disease require appropriate follow-up in adult specialty 
clinics. Although rare, cardiovascular defects might be 
diagnosed for the first time in adulthood181, but rou-
tine screening is not indicated. Patients with rare IC2 
CNVs and/or rearrangements that might predispose 
to long QT syndrome require follow-up throughout 
adulthood.
Infertility. Although congenital anomalies of the uro-
genital tract (for example, bicornuate uterus) have been 
described in BWSp178,181, there is no clear evidence of 
excess fertility problems in women with BWSp. Reduced 
fecundity has been described in affected males (com-
pared with females)182, but the frequency of infertility in 
men with BWSp is unknown.
Renal anomalies. Although examples of the diagno-
sis of renal anomalies in adults with BWSp have been 
reported178, it is assumed that if renal USS was per-
formed, renal abnormalities would usually be detected 
in childhood.
Although regular surveillance (for example, echo-
cardiography, renal function testing and evaluation of 
hearing) has been suggested for adults with BWSp181, 
in the absence of abnormalities detected during 
childhood surveillance, the detection rate of such 
investigations in asymptomatic adults with BWSp is 
likely to be low and could pose problems with health 
insurance. The consensus group agreed that a detailed 
clinical review and renal USS (Supplementary infor-
mation S5 (table)) should be undertaken at age 
16 years, and specific recommendations for contin-
ued surveillance based on only ongoing problems 
were agreed upon (TABLE 4, R68). Adults with BWSp 
should be encouraged to seek genetic counselling 
advice before starting a family (TABLE 4, R69). At that 
stage, any potential concerns about fertility can be 
reviewed and referrals for further investigation made 
as appropriate.
Psychological and counselling aspects
The diagnosis of a disorder such as BWSp can have 
wide-ranging effects on the psychological and social 
well-being of families. Although the precise effects 
will vary between families and will be influenced by 
individual medical and social factors, and considering 
that each family might face different challenges, it is 
important that all health-care professionals are aware 
of the wider non-medical issues that might be rele-
vant to the family (TABLE 4, R71). Information on the 
psychosocial aspects that might be specific to BWSp 
is sparse. In many cases, there is no previous relevant 
family history and the parents are not prepared for the 
diagnosis. Issues such as tumour risk can be worrying, 
and it is apparent that differing medical practices and 
recommendations might cause parental uncertainty 
and anxiety. A survey of parents of children with BWSp 
who have macroglossia revealed widespread parental 
concerns about the ‘negative cosmetic appearances’ of a 
large protruding tongue and persistent drooling, which 
led to strangers staring and questioning whether their 
children had learning difficulties128. Parents are also 
concerned that this might lead to teasing by other chil-
dren, and a retrospective questionnaire survey revealed 
an apparent increase in emotional difficulties and prob-
lems with peers in children with BWSp183. Health-care 
professionals should be aware that psychosocial diffi-
culties might occur and should be prepared to refer 
families to specialists such as genetic counsellors, social 
workers and psychologists, as appropriate. As support 
groups can have key roles in helping families adjust to 
the diagnosis, share their concerns and experiences 
and obtain the correct care and support, all families 
should be given the contact details of relevant groups 
(TABLE 4, R72).
Conclusions
The recommendations of the first international BWS 
consensus group described in this Consensus Statement 
provide a framework for improving the diagnosis and 
management of BWSp. As BWSp is characterized by 
complex genetics and variable multisystem pheno-
types, it is important that a lead clinician is identified 
for each patient (TABLE 4, R22) to ensure coordination 
of the numerous aspects of care throughout childhood 
(Supplementary information S5 (table)). The pro-
posed diagnostic and care pathways are intended to 
be practical and cost-effective (for example, targeting 
tumour surveillance to high-risk groups should reduce 
costs compared with universal surveillance strategies). 
Nevertheless, in some health-care systems and medico-
legal environments, further evidence might be required 
to shift clinical practice (for example, tumour surveil-
lance in North America). Thus, it is important that 
implementation of these consensus recommendations 
be accompanied by prospective audits in order to expand 
the evidence base for future consensus initiatives.
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